TEST:

MSIntuit™ CRC

"Owkin...and Proscia®...have announced a strategic partnership to streamline MSI testing for patients with colorectal cancer (CRC), the second most deadly cancer worldwide. As a first step in the collaboration, the companies will integrate Owkin’s MSIntuit CRC v2 with Proscia’s Concentriq software platform for studying its impact, and make it available as part of Proscia’s precision medicine AI portfolio to enable laboratories to keep pace with demand for MSI screening."

"Owkin and University Hospitals Birmingham NHS Foundation Trust (UHB) announced...a new five year research partnership to use artificial intelligence (AI) to accelerate the screening and diagnosis of a range of diseases, starting with colorectal cancer...The first research project in this collaboration aims to evaluate the performance of Owkin’s MSIntuit CRC solution in the United Kingdom across UHB’s cohort of 830 patients with primary colorectal adenocarcinoma."

We show that MSIntuit, while trained solely on resection specimens, is able to rule out more than 40% of non-MSI biopsies with high sensitivity. An enhanced version of the algorithm encompassing more resection training samples yields substantial improvement, ruling out more than 66% of non-MSI biopsies with high sensitivity. This study paves the way for the use of AI-based MSI pre-screening in clinical routine on CRC biopsy specimens.

AI adds relevant quantitative information to known features of MSI and MSS that can be used to objectively score and compare CRC cases. AI scores identify two distinct histological phenotypes for MLH1/PMS2 vs MSH2/MSH6. The clinical relevance should be further explored.

"Owkin...and Cerba Path...announced a new partnership. The two companies will work together to integrate Owkin’s cutting-edge AI-driven diagnostics into Cerba Path’s routine digital workflows and further validate AI-based tools for precision medicine...This partnership between Owkin and Cerba Path will have Cerba Path deploy Owkin’s technology to enhance pathologists’ and clinicians’ ability to accelerate precision medicine and deliver better patient care. Owkin’s AI diagnostics will benefit from Cerba Path’s fully digitized workflow and be able to reach a broader audience of pathologists who can access the Cerba Path platform remotely from any location in France."

"Owkin...announced an integration with international medical imaging IT and cybersecurity company Sectra...to integrate Owkin’s MSIntuit® CRC AI diagnostic into Sectra’s digital pathology solution. MSIntuit® CRC is the first CE-marked AI diagnostic for microsatellite instability (MSI) testing for colorectal cancer using digital H&E slides. It serves as a pre-screening tool for colorectal cancer patients that aims to streamline MSI testing, saving critical pathology resources by significantly reducing the proportion of patients that need to be fully screened by traditional methods."

MSIntuit yields a sensitivity of 0.96-0.98, a specificity of 0.47-0.46, and an excellent inter-scanner agreement (Cohen's κ: 0.82). By reaching high sensitivity comparable to gold standard methods while ruling out almost half of the non-MSI population, we show that MSIntuit can effectively serve as a pre-screening tool to alleviate MSI testing burden in clinical practice.

"In a peer-reviewed study published...a team of scientists from French-American techbio Owkin and pathology labs in France present a blind validation of MSIntuit™ CRC, a first-in-class AI-driven digital pathology diagnostic developed by Owkin, as a pre-screening tool aimed at optimizing the precision of diagnosis and treatment of colorectal cancer."

"Owkin has successfully validated its MSIntuit™ CRC AI solution for colorectal cancer (CRC) screening, a major milestone in the use of AI to further improve precision diagnostics for the benefit of patients. The technology is now being integrated into clinical workflows via Medipath, France's largest network of pathologists."

Her peer-reviewed research revolves around the intersection of traditional histopathology, molecular pathology and artificial intelligence. Katharina joined the medical team at Owkin as Head of Pathology.

"Five ground-breaking artificial intelligence biology research abstracts led by AI biotech Owkin have been published by ESMO ahead of its 2022 Congress...The obtained results showed the ability of RlapsRisk to generalize on independent data and thus endorse the soundness of the method. Furthermore, additional analysis brings to light the clinical value of RlapsRisk and that it could be used for therapeutic de-escalation purposes."

"Artificial intelligence (AI) biotech company Owkin...announced that two first-in-class rapid, affordable AI-based diagnostic solutions designed to improve outcomes for patients with breast cancer and colorectal cancer have been approved for use in Europe...Owkin Dx RlapsRisk™ BC and Owkin Dx MSIntuit™ CRC have received CE-IVD approval for diagnostic use in the European Union. By using AI to analyze digital pathology images, they are designed to help clinicians make precision medicine – diagnostic and treatment based on a patient's individual characteristics – more accessible to more patients at an earlier stage of their disease."